A Phase 1/2 interventional study of elamipretide (low dose) and elamipretide (intermediate dose) in Mitochondrial Myopathy, sponsored by Stealth BioTherapeutics Inc.. Completed at 4 sites in United States. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-12-27.
Sponsored by Stealth BioTherapeutics Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Mitochondrial Myopathies with a site in United States — 6 open to participants now, 8 under way, none of them phase 3. Mitochondrial Myopathies · United States.
Among the 19 studies in Mitochondrial Myopathies with a site in United States, this one is the 8th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2015, is one of 2 in phase 1/2, and was the 5th registered.
46 studies on the registry are indexed under Mitochondrial Myopathies; 14 are open to participants now.
Browse Mitochondrial Myopathies studies →6 of the 19 studies in Mitochondrial Myopathies with a site in United States are open now. Recruiting first, the newest first:
The POLG Foundation · Sites in United States, Australia, Denmark and 6 more countries
Children's Hospital of Philadelphia · Sites in United States
Ages 18–65 · Healthy volunteers
Children's Hospital of Philadelphia · Sites in United States
Ages 10–60 · Healthy volunteers
Children's Hospital of Philadelphia · Sites in United States
Ages 18–65 · Healthy volunteers
Children's Hospital of Philadelphia · Sites in United States
Ages 0–100 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Mitochondrial Myopathies studies recruiting now, 8 (62%) set no upper age limit and 4 (31%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.
This study: 16 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 1
First in 1978; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is above the median of 24 across 31 interventional studies indexed under Mitochondrial Myopathies.
Median enrollment 50 across the 12 interventional studies, 215 across the 7 observational. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Stealth BioTherapeutics Inc., one of the names counted as Mighty Therapeutics. Under that name alone:
Stealth BioTherapeutics Inc. is the lead sponsor of 30 studies on the registry; 3 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Mighty Therapeutics has 4 studies filed under Mitochondrial Myopathies — fewer than ten, so there is no comparison to draw.
5 of the studies in Mitochondrial Myopathies with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05590468Ralitza GavrilovaA Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy | 2026-11 |
| NCT01694940Columbia UniversityNorth American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | 2026-12-31 |
| NCT04086329Children's Hospital of PhiladelphiaValidation of Oxygen Nanosensor in Mitochondrial Myopathy | 2027-08-01 |
| NCT06819683Children's Hospital of PhiladelphiaValidation of Nanosensor Oxygen Measurement | 2027-09 |
| NCT05569122Children's Hospital of PhiladelphiaApplying pGz in Mitochondrial Disease | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 19 studies in Mitochondrial Myopathies with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 1/2, multi-center, randomized, double-blind, multiple ascending dose, placebo-controlled study that enrolled 36 subjects with mitochondrial myopathy associated with genetically confirmed mitochondrial disease to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MTP-131 in this patient population.
This multi-center, randomized, double-blind, placebo-controlled study enrolled 36 subjects into 3 cohorts of 12 subjects each to evaluate treatment with 3 ascending doses of intravenous elamipretide (0.01, 0.10, and 0.25 mg/kg/hr infused for 2 hours). After each cohort, a Safety Monitoring Board (SMB) determined if dose escalation to the next higher dose of elamipretide was warranted. Each cohort went through 3 distinct periods: Screening, Treatment, and Follow-up.
The Screening Period started with informed consent and may have lasted up to 40 days. During this period, screening procedures to determine subject eligibility for the study occurred, including confirmation of disease, which incorporated a committee review of the investigator-submitted diagnosis and genetic results. The Treatment Period began on Day 1 (Visit 2) and lasted for 5 days (until Day 5 [Visit 6]). Within each cohort, 9 subjects were randomized to active drug and 3 subjects were randomized to placebo on Day 1 and subjects received treatment once a day for 5 consecutive days. Safety, tolerability, and efficacy measures were performed at pre-specified times. The Follow-up Period began at the time of discharge on Day 5. Subjects returned to the study center for the Follow-up Visit on Day 7 (+1 day).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participated in another interventional clinical trial within 3 months of the screening visit or is currently enrolled in a non-interventional clinical trial judged by the Investigator to be incompatible with the current trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
elamipretide 0.01 mg/kg/hr infused for 2 hours for 5 days
Drug: elamipretide (low dose)
elamipretide 0.10 mg/kg/hr infused for 2 hours for 5 days
Drug: elamipretide (intermediate dose)
elamipretide 0.25 mg/kg/hr infused for 2 hours for 5 days
Drug: elamipretide (high dose)
In each cohort, subjects received either IV elamipretide given once daily for 2 hours for 5 days or matching placebo.
Drug: Placebo
elamipretide (0.01 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
Also known as: MTP-131
elamipretide (0.10 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
Also known as: MTP-131
elamipretide (0.25 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
Also known as: MTP-131
placebo (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days
Change in Distance Walked (Meters) on the 6-minute Walk Test (6MWT)
Change in distance walked as measured by meters on the 6-minute walk test from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
Time frame: Assessed at Baseline, Day 5 (end-of-treatment visit)
Change in Maximum Oxygen Uptake (ml/kg/Min)
Change in maximum oxygen uptake as measured by mL/kg/min from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
Time frame: Baseline, Day 5
Change in Ventilatory Efficiency (VE/VCO2 Slope)
Change in ventilatory efficiency as measured by the VE/VCO2 slope from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
Time frame: Baseline, Day 5
Change in Aerobic Efficiency (ΔO2 Consumption/Δ Work Ratio)
Change in aerobic efficiency as measured by ΔO2 consumption/Δ work ratio from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
Time frame: Baseline, Day 5
Change in Oxygen Utilization (ΔVO2/ΔlogVE Ratio)
Change in oxygen utilization as measured by ΔVO2/ΔlogVE ratio from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
Time frame: Baseline, Day 5
Change in Oxygen Uptake Kinetics (Mean Response Time as Measured by Seconds)
Change in oxygen uptake kinetics (mean response time) as measured by seconds from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
Time frame: Baseline, Day 5
Change in Pre-exercise Lactate Levels (mg/dL)
Change in pre-exercise lactate levels as measured by mg/dL from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
Time frame: Baseline, Day 5
Change in Post-exercise Lactate Levels (mg/dL)
Change in post-exercise lactate levels as measured by mg/dL from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
Time frame: Baseline, Day 5
Change in Peak Respiratory Exchange Ratio (VCO2/VO2)
Change in peak respiratory exchange ratio as measured by VCO2/VO2 from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
Time frame: Baseline, Day 5
Change in Peak Respiratory Rate (Breaths/Min)
Change in peak respiratory rate as measured by breaths/min from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
Time frame: Baseline, Day 5
Change in Peak Ventilation (L/Min)
Change in peak ventilation as measured by L/min from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
Time frame: Baseline, Day 5
Change in Peak Heart Rate (Beats/Min)
Change in peak heart rate as measured by beats per minute from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
Time frame: Baseline, Day 5
Change in Peak Oxygen Saturation (% O2-saturated Hemoglobin)
Change in peak oxygen saturation as measured by percentage of O2-saturated hemoglobin from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
Time frame: Baseline, Day 5
Change in Peak Systolic Blood Pressure (mmHg)
Change in peak systolic blood pressure as measured by mmHg from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
Time frame: Baseline, Day 5
Change in Peak Diastolic Blood Pressure (mmHg)
Change in peak diastolic blood pressure as measured by mmHg from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
Time frame: Baseline, Day 5
Change in Peak Borg Dyspnea
Change in peak Borg dyspnea as measured by 0-10 with 0 meaning no breathlessness and 10 meaning maximal breathlessness from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
Time frame: Baseline, Day 5
Change in VO2 Anaerobic Threshold (mL)
Change in VO2 anaerobic threshold as measured by mL from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
Time frame: Baseline, Day 5
Change in Watts
Change in watts from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
Time frame: Baseline, Day 5
Change in Temperature (°C)
Change in temperature as measured by units of Celsius from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
Time frame: Baseline, Day 5
Change in ECG-PR Interval (Msec)
Change in PR interval as measured by ECG in milliseconds from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
Time frame: Baseline, Day 5
Change in ECG-QRS Complex (Msec)
Change in QRS complex as measured by ECG in msec from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
Time frame: Baseline, Day 5
Change in ECG-QT Interval (Msec)
Change in QT interval as measured by ECG in msec from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
Time frame: Baseline, Day 5
Change in ECG-QTc Interval (Msec)
Change in QTc interval as measured by ECG in msec from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
Time frame: Baseline, Day 5
Number of Participants Who Had Suicide Ideation, Suicidal Behavior, or Non-suicidal Self-injurious Behavior Post-screening.
Number of participants with suicide ideation, suicidal behavior, or non-suicidal self-injurious behavior post-screening as measured on Days 1-5, and Day 7 on the Columbia Suicide Severity Rating Scale (CSSRS). A yes/no binary response is utilized in the following ten categories: 1 - Wish to be Dead; 2 - Non-specific Active Suicidal Thoughts; 3 - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; 4 - Active Suicidal Ideation with Some Intent to Act, without Specific Plan; 5 - Active Suicidal Ideation with Specific Plan and Intent; 6 - Preparatory Acts or Behavior; 7 - Aborted Attempt; 8 - Interrupted Attempt; Category 9 - Actual Attempt (non-fatal); 10 - Completed Suicide. A yes/no binary response is also utilized in assessing self-injurious behavior without suicidal intent. A lower score means a better outcome whereas a higher score means a worse outcome.
Time frame: Days 1-5 and Day 7.
Change in Creatine Phosphokinase (IU/L)
Change in Creatine Phosphokinase as measured by IU/L from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
Time frame: Baseline, Day 5
Change in Alanine Aminotransferase (ALT) (U/L)
Change in Alanine aminotransferase (ALT) as measured by (U/L) from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
Time frame: Baseline, Day 5
Change in Aspartate Aminotransferase (AST) (U/L)
Change in aspartate aminotransferase (AST) as measured by U/L from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
Time frame: Baseline, Day 5
Change in Eosinophils (10^9 Cells/L)
Change in eosinophils as measured by (10\^9 cells/L) from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
Time frame: Baseline, Day 5
Study Centers: Akron Children's Hospital; Massachusetts General Hospital; University of Pittsburgh School of Medicine; University of California, San Diego
| Milestone | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| Started | 9 | 9 | 9 | 9 |
| Completed | 9 | 9 | 9 | 9 |
| Not completed | 0 | 0 | 0 | 0 |
Change in distance walked as measured by meters on the 6-minute walk test from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
| meters | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| Change in Distance Walked (Meters) on the 6-minute Walk Test (6MWT) | 13.5 (-72 to 86) | 36.5 (-20 to 107) | 64.5 (4 to 133) | 20.4 (-37 to 90) |
Change in maximum oxygen uptake as measured by mL/kg/min from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
| ml/kg/min | Low Dose | Intermediate | High | Placebo |
|---|---|---|---|---|
| Change in Maximum Oxygen Uptake (ml/kg/Min) | 0.35 ± 2.617 | 2.36 ± 2.714 | 0.64 ± 3.121 | 2.14 ± 3.137 |
Change in ventilatory efficiency as measured by the VE/VCO2 slope from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
| VE/VCO2 slope | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| Change in Ventilatory Efficiency (VE/VCO2 Slope) | 0.749 ± 2.9412 | -0.671 ± 5.4024 | -1.681 ± 3.2834 | -1.375 ± 5.5801 |
Change in aerobic efficiency as measured by ΔO2 consumption/Δ work ratio from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
| ΔO2 consumption/Δwork ratio | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| Change in Aerobic Efficiency (ΔO2 Consumption/Δ Work Ratio) | -0.234 ± 4.3414 | 0.643 ± 2.7507 | -0.214 ± 1.9727 | 0.738 ± 3.5959 |
Change in oxygen utilization as measured by ΔVO2/ΔlogVE ratio from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
| ΔVO2/ΔlogVE ratio | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| Change in Oxygen Utilization (ΔVO2/ΔlogVE Ratio) | -118.87 ± 229.105 | 184.99 ± 410.093 | 90.13 ± 116.281 | 166.50 ± 479.145 |
Change in oxygen uptake kinetics (mean response time) as measured by seconds from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
| seconds | Low Dose | Intermediate | High | Placebo |
|---|---|---|---|---|
| Change in Oxygen Uptake Kinetics (Mean Response Time as Measured by Seconds) | 6.40 ± 11.402 | -2.49 ± 26.830 | -9.75 ± 26.288 | -7.47 ± 14.357 |
Change in pre-exercise lactate levels as measured by mg/dL from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
| mg/dL | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| Change in Pre-exercise Lactate Levels (mg/dL) | 3.4 ± 9.00 | 13.8 ± 18.30 | 0.4 ± 10.25 | 4.4 ± 14.06 |
Change in post-exercise lactate levels as measured by mg/dL from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
| mg/dL | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| Change in Post-exercise Lactate Levels (mg/dL) | 6.9 ± 11.87 | 10.6 ± 42.93 | 4.3 ± 22.10 | 8.4 ± 13.21 |
Change in peak respiratory exchange ratio as measured by VCO2/VO2 from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
| VCO2/VO2 ratio | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| Change in Peak Respiratory Exchange Ratio (VCO2/VO2) | 0.109 ± 0.0741 | 0.114 ± 0.1803 | 0.010 ± 0.0561 | 0.133 ± 0.1297 |
Change in peak respiratory rate as measured by breaths/min from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
| breaths/min | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| Change in Peak Respiratory Rate (Breaths/Min) | 1.4 ± 6.54 | -0.7 ± 5.72 | 0.9 ± 6.24 | 8.2 ± 5.26 |
Change in peak ventilation as measured by L/min from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
| L/min | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| Change in Peak Ventilation (L/Min) | 2.70 ± 8.692 | 8.87 ± 7.975 | 2.49 ± 8.303 | 8.47 ± 8.564 |
Change in peak heart rate as measured by beats per minute from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
| beats/min | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| Change in Peak Heart Rate (Beats/Min) | 10.1 ± 11.15 | 16.7 ± 13.02 | 4.5 ± 9.58 | 3.8 ± 7.85 |
Change in peak oxygen saturation as measured by percentage of O2-saturated hemoglobin from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
| percentage of O2-saturated hemoglobin | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| Change in Peak Oxygen Saturation (% O2-saturated Hemoglobin) | 0.0 ± 1.69 | 0.1 ± 1.07 | 0.6 ± 0.74 | 0.3 ± 1.60 |
Change in peak systolic blood pressure as measured by mmHg from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
| mmHg | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| Change in Peak Systolic Blood Pressure (mmHg) | 16.7 ± 21.00 | -1.5 ± 36.47 | 16.0 ± 12.71 | -2.7 ± 21.84 |
Change in peak diastolic blood pressure as measured by mmHg from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
| mmHg | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| Change in Peak Diastolic Blood Pressure (mmHg) | 0.6 ± 12.67 | -1.4 ± 11.13 | -2.5 ± 9.07 | -6.6 ± 12.74 |
Change in peak Borg dyspnea as measured by 0-10 with 0 meaning no breathlessness and 10 meaning maximal breathlessness from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
| Units on a scale | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| Change in Peak Borg Dyspnea | -2.00 ± 2.00 | -2.2 ± 2.23 | -1.4 ± 1.30 | -0.4 ± 1.70 |
Change in VO2 anaerobic threshold as measured by mL from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
| mL | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| Change in VO2 Anaerobic Threshold (mL) | 30.00 ± 83.93 | 10.8 ± 80.35 | 1.6 ± 42.17 | 42.0 ± 51.89 |
Change in watts from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
| watts | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| Change in Watts | 9.6 ± 14.15 | 13.9 ± 12.48 | 5.4 ± 10.03 | 4.4 ± 11.87 |
Change in temperature as measured by units of Celsius from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
| °C | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| Change in Temperature (°C) | -0.3 ± 0.54 | 0.2 ± 0.42 | 0.1 ± 0.28 | 0.0 ± 0.67 |
Change in PR interval as measured by ECG in milliseconds from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
| msec | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| Change in ECG-PR Interval (Msec) | -3.2 ± 7.77 | 8.3 ± 7.05 | 9.1 ± 9.55 | -1.6 ± 15.61 |
Change in QRS complex as measured by ECG in msec from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
| msec | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| Change in ECG-QRS Complex (Msec) | 1.2 ± 7.14 | 2.3 ± 6.56 | -2.2 ± 8.86 | 0.8 ± 5.78 |
Change in QT interval as measured by ECG in msec from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
| msec | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| Change in ECG-QT Interval (Msec) | -6.0 ± 30.53 | -4.8 ± 12.94 | -16.7 ± 81.02 | -1.3 ± 18.49 |
Change in QTc interval as measured by ECG in msec from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
| msec | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| Change in ECG-QTc Interval (Msec) | 3.4 ± 20.17 | 1.3 ± 20.24 | -23.2 ± 77.53 | 6.7 ± 17.28 |
Number of participants with suicide ideation, suicidal behavior, or non-suicidal self-injurious behavior post-screening as measured on Days 1-5, and Day 7 on the Columbia Suicide Severity Rating Scale (CSSRS). A yes/no binary response is utilized in the following ten categories: 1 - Wish to be Dead; 2 - Non-specific Active Suicidal Thoughts; 3 - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; 4 - Active Suicidal Ideation with Some Intent to Act, without Specific Plan; 5 - Active Suicidal Ideation with Specific Plan and Intent; 6 - Preparatory Acts or Behavior; 7 - Aborted Attempt; 8 - Interrupted Attempt; Category 9 - Actual Attempt (non-fatal); 10 - Completed Suicide. A yes/no binary response is also utilized in assessing self-injurious behavior without suicidal intent. A lower score means a better outcome whereas a higher score means a worse outcome.
| Participants | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| Number of Participants Who Had Suicide Ideation, Suicidal Behavior, or Non-suicidal Self-injurious Behavior Post-screening. | 0 | 0 | 0 | 0 |
Change in Creatine Phosphokinase as measured by IU/L from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
| IU/L | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| Change in Creatine Phosphokinase (IU/L) | -24.8 ± 25.10 | -161.7 ± 176.49 | -101.2 ± 149.07 | -154.9 ± 232.99 |
Change in Alanine aminotransferase (ALT) as measured by (U/L) from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
| U/L | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| Change in Alanine Aminotransferase (ALT) (U/L) | 19.3 ± 42.24 | -3.0 ± 4.92 | -5.3 ± 3.28 | 1.1 ± 5.80 |
Change in aspartate aminotransferase (AST) as measured by U/L from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
| U/L | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| Change in Aspartate Aminotransferase (AST) (U/L) | 5.6 ± 9.93 | -2.2 ± 10.38 | -12.6 ± 18.08 | -4.4 ± 13.07 |
Change in eosinophils as measured by (10\^9 cells/L) from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).
| 10^9 cells/L | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| Change in Eosinophils (10^9 Cells/L) | 0.06 ± 0.073 | 0.08 ± 0.097 | -0.01 ± 0.064 | 0.04 ± 0.088 |
Collected over 7 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Low Dose | 0/9 (0%) | 0/9 (0%) | 7/9 (77.8%) |
| Intermediate Dose | 0/9 (0%) | 0/9 (0%) | 7/9 (77.8%) |
| High Dose | 0/9 (0%) | 0/9 (0%) | 5/9 (55.6%) |
| Placebo | 0/9 (0%) | 0/9 (0%) | 5/9 (55.6%) |
| Event | Low Dose | Intermediate Dose | High Dose | Placebo |
|---|---|---|---|---|
| HeadacheNervous system disorders | 1/9 | 1/9 | 2/9 | 2/9 |
| DizzinessNervous system disorders | 2/9 | 1/9 | 0/9 | 0/9 |
| Abdominal painGastrointestinal disorders | 0/9 | 2/9 | 0/9 | 0/9 |
| FlatulenceGastrointestinal disorders | 1/9 | 0/9 | 0/9 | 1/9 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/9 | 0/9 | 0/9 | 1/9 |
| ConstipationGastrointestinal disorders | 0/9 | 0/9 | 0/9 | 1/9 |
| NauseaGastrointestinal disorders | 0/9 | 1/9 | 0/9 | 0/9 |
| Injection site bruisingGeneral disorders | 1/9 | 0/9 | 0/9 | 0/9 |
| ThirstGeneral disorders | 0/9 | 0/9 | 0/9 | 1/9 |
| Vessel puncture site haemorrhageGeneral disorders | 0/9 | 1/9 | 0/9 | 0/9 |
| Age, Continuous(years) | Low Dose | Intermediate Dose | High Dose | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 40.8 ± 11.32 | 45.0 ± 14.09 | 42.3 ± 16.84 | 41.9 ± 15.83 | 42.5 ± 14.12 |
| Sex: Female, Male(Participants) | Low Dose | Intermediate Dose | High Dose | Placebo | Total |
|---|---|---|---|---|---|
| Female | 7 | 8 | 6 | 9 | 30 |
| Male | 2 | 1 | 3 | 0 | 6 |
The record gives a start of Feb 2015, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2019, 3 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elamipretide
Stealth BioTherapeutics Inc. →